{"id":33377,"date":"2017-10-31T10:28:18","date_gmt":"2017-10-31T09:28:18","guid":{"rendered":"http:\/\/www.fedaiisf.it\/?p=33377"},"modified":"2017-10-31T10:28:18","modified_gmt":"2017-10-31T09:28:18","slug":"grecia-guerra-del-farmaco-tsipras-le-case-farmaceutiche","status":"publish","type":"post","link":"https:\/\/www.fedaiisf.it\/en\/grecia-guerra-del-farmaco-tsipras-le-case-farmaceutiche\/","title":{"rendered":"Greece. Drug war between Tsipras and pharmaceutical companies"},"content":{"rendered":"<h2 class=\"sottotitolo\">It is increasingly difficult for pharmaceutical companies to do business in Greece. And so a company has decided to withdraw an innovative oncological drug from the market.<\/h2>\n<p><a href=\"http:\/\/www.affaritaliani.it\/affari-europei\/salute-guerra-del-farmaco-in-grecia-tra-tsipras-le-case-farmaceutiche-507385.html\" target=\"_blank\" rel=\"noopener\">Affaritaliani \u2013 Tuesday, 31 October 2017<\/a><\/p>\n<p>A multinational pharmaceutical company has decided to withdraw an innovative cancer drug from the Greek market, claiming that its price has decreased by 50% due to government regulatory interventions in the pharmaceutical sector.<\/p>\n<p><strong>Drug multinationals fleeing Greece<\/strong><\/p>\n<p>St<img decoding=\"async\" class=\"alignright\" src=\"http:\/\/antikleidi.com\/wp-content\/uploads\/2014\/11\/eopyy.jpg\" alt=\"Risultati immagini per eopyy\" \/>According to a letter seen by Euractiv, which reports the news, the pharmaceutical company notified the Greek health ministry on October 30 of its decision to withdraw a new cancer drug from the list of prescribed medicines, meaning that the drug will no longer be refunded.<\/p>\n<p><strong>Withdrawal of some innovative medicines<\/strong><\/p>\n<p>The measures that the Greek government has taken in relation to the international bailout have put a lot of pressure on the pharmaceutical companies which have threatened to withdraw some products from the market or to stop introducing new drugs.<\/p>\n<p><strong>Too many taxes on innovative drugs to stay on the market<\/strong><\/p>\n<p>The reason, say the pharmaceutical multinationals, is a measure that Athens recently introduced and which provides for a levy of up to 25% on the turnover generated by new patent-protected drugs. This sort of tax has been retroactively applied to all innovative medicines since January 2017. In addition to this, the Greek government decided in May 2017 to impose a 25% registration tax on new medicines.<\/p>\n<p>Related news:\u00a0<a href=\"https:\/\/www.euractiv.com\/section\/health-consumers\/news\/pharmaceutical-company-withdraws-oncology-drug-from-greek-market\/\" target=\"_blank\" rel=\"noopener\">Pharmaceutical company withdraws oncology drug from Greek market<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>Per le case farmaceutiche \u00e8 sempre pi\u00f9 difficile fare affari in Grecia. E cos\u00ec una ditta ha deciso di ritirare dal mercato un innovativo farmaco oncologico. affaritaliani &#8211;\u00a0Marted\u00ec, 31 ottobre 2017 Una multinazionale farmaceutica ha deciso di ritirare un medicinale oncologico innovativo dal mercato greco, sostenendo che il suo prezzo \u00e8 diminuito del 50% a &hellip;<\/p>","protected":false},"author":4,"featured_media":19932,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[29],"class_list":["post-33377","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizie","tag-prezzo-farmaci"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/33377","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/comments?post=33377"}],"version-history":[{"count":0,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/33377\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media\/19932"}],"wp:attachment":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media?parent=33377"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/categories?post=33377"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/tags?post=33377"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}